Clinical outcomes of a collaborative, home-based postdischarge warfarin management service

Annals of Pharmacotherapy

Volumn 45, Issue 3, 2011, Pages 325-334

  Stafford, Leanne ^a   Peterson, Gregory M ^a   Bereznicki, Luke R E ^a   Jackson, Shane L ^a   Van Tienen, Ella C ^a   Angley, Manya T ^b   Bajorek, Beata V ^c   McLachlan, Andrew J ^c   Mullan, Judy R ^d   Misan, Gary M H ^b   Gaetani, Luigi ^d  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Adverse drug events; Community pharmacy services; International normalized ratio; Patient discharge; Warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DRUG SAFETY; FEMALE; GENERAL PRACTITIONER; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HOME CARE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACIST; PHARMACIST ATTITUDE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; AUSTRALIA; COHORT STUDIES; FEMALE; HOME CARE SERVICES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PATIENT DISCHARGE; PATIENT READMISSION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WARFARIN;

EID: 79952636526     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P617     Document Type: Article

References (39)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ed. Chest 2008;133(suppl):160S-98S. DOI 10.1378/chest.08-0670
2. Australian Council for Safety and Quality in Health. Second national report on patient safety: improving medication safety. Canberra: Safety and Quality Council, 2002.
3. Roughead E. The nature and extent of drug-related hospitalisations in Australia. J Qual Clin Pract 1999;19:19-22. DOI 10.1046/j.1440-1762.1999.00288.x (Pubitemid 29111573)
4. Rigby K, Clark RB, Runciman WB. Adverse events in health care: setting priorities based on economic evaluation. J Qual Clin Pract 1999;19:7-12. DOI 10.1046/j.1440-1762.1999.00301.x (Pubitemid 29111571)
5. Gallus AS. Towards the safer use of warfarin I: an overview. J Qual Clin Pract 1999;19:55-9. DOI 10.1046/j.1440-1762.1999.00295.x (Pubitemid 29111581)
6. Beyth RJ. Hemorrhagic complications of oral anticoagulant therapy. Clin Geriatr Med 2001;17:49. DOI 10.1016/S0749-0690%2805%2970105-1
7. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(suppl):108S-21S. DOI 10.1378/chest.126.3-suppl.287S
8. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239-45.
9. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. Can Med Assoc J 2008;179:235-44. DOI 10.1503/cmaj.080171
10. Palareti G, Legnani C, Cosmi B, Guazzaloca G, Cini M, Mattarozzi S. Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. J Thromb Haemost 2005;3:955-61. DOI 10.1111/j.1538-7836.2005.01330.x (Pubitemid 41632826)
11. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96. DOI 10.1161/CIRCULATIONAHA.106.653048 (Pubitemid 46842784)
12. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-66. DOI 10.1378/chest.129.5.1155
13. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005;127:2049-56. DOI 10.1378/chest.127.6.2049
14. Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Warfarin use in the elderly: the nurses' perspective. Aust J Adv Nurs 2006;23:19-25.
15. Bereznicki LR, Stafford L, Jeffrey EC, Peterson GM, Jackson SL. Who is responsible for the care of patients treated with warfarin therapy (comment)? Med J Aust 2009;191:575-6. Author reply: 6.
16. Tang EOYL, Lai CSM, Lee KKC, Wong RSM, Cheng G, Chan TYK. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother 2003;37:34-9. DOI 10.1345/aph.1A198 (Pubitemid 36068595)
17. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000;133:687-95.
18. Barcellona D, Contu P, Marongiu F. Patient education and oral anticoagulant therapy. Haematologica 2002;87:1081-6. (Pubitemid 35192221)
19. Ansell JE. Empowering patients to monitor and manage oral anticoagulation therapy. J Am Med Assoc 1999;281:182-3. DOI 10.1001/jama.281.2.182 (Pubitemid 29045353)
20. Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164:2044-50. (Pubitemid 39390563)
21. Pearson B, Skelly R, Wileman D, Masud T. Unplanned readmission to hospital: a comparison of the views of general practitioners and hospital staff. Age Ageing 2002;31:141-3. DOI 10.1093/ageing/31.2.141
22. Forster AJ, Murff HJ, Peterson JF, Gandhi TK, Bates DW. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 2003;138:161-7. (Pubitemid 36231621)
23. Jackson S, Peterson G, Vial J, Jupe D. Suboptimal anticoagulant management in patients after hospital initiation of warfarin. Aust Fam Physician 2004;33:477-8.
24. Jackson SL, Peterson GM, Vial JH, Jupe DML. Improving the outcomes of anticoagulation: an evaluation of home follow-up of warfarin initiation. J Intern Med 2004;256:137-44. DOI 10.1111/j.1365-2796.2004.01352.x (Pubitemid 38998260)
25. Medicare Australia. Home Medicines Review (HMR). www.medicare australia.gov.au/provider/pbs/fourth-agreement/hmr.jsp (accessed 2010 Apr 23).
26. Peterson GM. Facilitating quality use of medicines between hospital and community (Med-E-Support). Funded by the Australian Government Department of Health and Ageing, through the Third Community Pharmacy Agreement Research and Development Program. www.guild.org. au/research/project-display.asp?id = 271 (accessed 2010 Apr 23).
27. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin - incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989;87:144-52. DOI 10.1016/S0002-9343(89)80689-8 (Pubitemid 19201634)
28. Stafford L, Peterson GM, Bereznicki LR, Jackson SL, van Tienen EC. Training Australian pharmacists for participation in a collaborative, home-based post-discharge warfarin management service. Pharm World Sci 2010; 32:637-42. DOI 10.1007/s11096-010-9416-7
29. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998;105:91-9. DOI 10.1016/S0002-9343(98)00198-3 (Pubitemid 28405230)
30. Roberts GW, Helboe T, Nielsen CB, et al. Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother 2003;37:799-803. DOI 10.1345/aph.1A372 (Pubitemid 36618363)
31. Gaetani L, Thomas B. Discharge medication (letter). Aust Prescr 2006; 29:121.
32. Schulman S, Kearon C, on behalf of the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4. DOI 10.1111/j.1538-7836. 2009.03678.x
33. Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150:293-300.
34. Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Expert Rev Cardiovasc Ther 2008;6:57-70. DOI 10.1586/14779072.6.1.57
35. eMIMS. St Leonards: CMPMedica Australia Pty Ltd; 1996-2008. www.mimsonline.com.au (accessed 2008 Sept 19).
36. Rahman M, BinEsmael TM, Payne N, Butchart EG. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother 2006;40: 397-401. DOI 10.1345/aph.1G407
37. Heidinger KS, Bernardo A, Taborski U, Muller-Berghaus G. Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis. Thrombosis Research 2000;98: 287-93. DOI 10.1016/S0049-3848(00)00181-X (Pubitemid 30255932)
38. Australian Pharmaceutical Advisory Council. Guiding principles to achieve continuity in medication management. Canberra: Commonwealth of Australia; 2005.
39. Angley M, Ponniah A, Bong J, et al. Implementing and evaluating a parallel postdischarge Home Medicines Review (HMR) model. Funded by the Australian Government Department of Health and Ageing under the Fourth Community Pharmacy Agreement Research and Development Program. Adelaide: University of South Australia, 2010.